logo
  

Satsuma Pharma: STS101 Fails To Meet Statistical Significance On Co-primary Endpoints

Satsuma Pharmaceuticals, Inc. (STSA) announced topline results from its phase 3 EMERGE efficacy trial of STS101 powder as an acute treatment for migraine. The company said topline data from the study did not show statistically significant differences between either dosage strength of STS101 and placebo on co-primary endpoints of freedom from pain and most bothersome symptom at two hours post-administration. STS101 was well-tolerated in the trial.

The company said analysis of EMERGE trial data is ongoing, and it expects to provide a detailed update on its business plans after these analyses are completed.

Headquartered in South San Francisco, California, Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing STS101. Shares of Satsuma Pharma were down 83% in pre-market trade on Thursday.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Home improvement retailer Lowe's Cos., Inc. reported Wednesday an increase in earnings per share for the second quarter that also topped analysts' estimates. However, quarterly sales edged down and missed expectations. The company also reaffirmed its guidance range for the full-year 2022. While reporting financial results for the second quarter on Wednesday, off-price retailer TJX Companies, Inc. (TJX) provided financial outlook for the third and the fourth quarters as well as slashed its guidance for the full-year 2023. For the third quarter, the company projects earnings in a range... American Airlines announced an agreement to purchase up to 20 Overture supersonic jets, the world's fastest airliner, from transportation start-up Boom Supersonic, with an option for an additional 40. Overture, which is expected to carry passengers at twice the speed of the fastest commercial aircraft available at present, would provide an important new speed advantage to American's fleet.
Follow RTT